NYSE:NGVT - Ingevity Stock Price, Forecast & News

Ingevity trades on the New York Stock Exchange (NYSE) under the ticker symbol "NGVT."

Ingevity Corp (NYSE:NGVT) announced its quarterly earnings results on Monday, February, 3rd. The company reported $1.10 EPS for the quarter, topping the Zacks' consensus estimate of $1.03 by $0.07. The business had revenue of $303.40 million for the quarter, compared to analysts' expectations of $305.09 million. Ingevity had a return on equity of 51.91% and a net margin of 14.21%. The business's quarterly revenue was up 8.9% on a year-over-year basis. During the same period in the previous year, the firm earned $1.07 EPS. View Ingevity's Earnings History.

Ingevity is scheduled to release their next quarterly earnings announcement on Wednesday, May 6th 2020. View Earnings Estimates for Ingevity.

Ingevity updated its FY 2020 Pre-Market earnings guidance on Monday, February, 3rd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $1.3-1.35 billion, compared to the consensus revenue estimate of $1.37 billion.

8 brokers have issued twelve-month target prices for Ingevity's shares. Their forecasts range from $83.00 to $130.00. On average, they expect Ingevity's share price to reach $106.75 in the next year. This suggests a possible upside of 64.2% from the stock's current price. View Analyst Price Targets for Ingevity.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ingevity in the last year. There are currently 2 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Ingevity.

Press coverage about NGVT stock has trended very positive recently, InfoTrie reports. InfoTrie scores the sentiment of media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Ingevity earned a news sentiment score of 3.5 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 4.0 out of 10, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near term. View News Stories for Ingevity.

Some companies that are related to Ingevity include Johnson Matthey (JMPLY), Ashland Global (ASH), Huntsman (HUN), KURARAY CO LTD/ADR (KURRY), W. R. Grace & Co (GRA), Univar (UNVR), Balchem (BCPC), Chemours (CC), Olin (OLN), Innospec (IOSP), PQ Group (PQG), GCP Applied Technologies (GCP), Livent (LTHM), Innophos (IPHS) and Hawkins (HWKN).

Based on aggregate information from My MarketBeat watchlists, some companies that other Ingevity investors own include AbbVie (ABBV), Pfizer (PFE), Verizon Communications (VZ), Costco Wholesale (COST), NVIDIA (NVDA), Alibaba Group (BABA), General Electric (GE), Quaker Chemical (KWR), Paypal (PYPL) and Zebra Technologies (ZBRA).

Ingevity's stock is owned by a number of of retail and institutional investors. Top institutional investors include Franklin Resources Inc. (3.22%), State Street Corp (3.15%), Massachusetts Financial Services Co. MA (2.61%), Victory Capital Management Inc. (1.96%), Goldman Sachs Group Inc. (1.96%) and Alliancebernstein L.P. (1.93%). Company insiders that own Ingevity stock include D Michael Wilson, John C Fortson, Katherine Pryor Burgeson and Phillip John Platt. View Institutional Ownership Trends for Ingevity.

NGVT stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Capital Research Global Investors, Panagora Asset Management Inc., Amundi Pioneer Asset Management Inc., Moody Aldrich Partners LLC, Mesirow Financial Investment Management Equity Management, Marshall Wace North America L.P. and Chartwell Investment Partners LLC. Company insiders that have sold Ingevity company stock in the last year include John C Fortson, Katherine Pryor Burgeson and Phillip John Platt. View Insider Buying and Selling for Ingevity.

NGVT stock was purchased by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Artisan Partners Limited Partnership, Scopus Asset Management L.P., Pictet Asset Management Ltd., California Public Employees Retirement System, Massachusetts Financial Services Co. MA, Thrivent Financial for Lutherans and UBS Group AG. Company insiders that have bought Ingevity stock in the last two years include D Michael Wilson and John C Fortson. View Insider Buying and Selling for Ingevity.

Shares of NGVT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of NGVT stock can currently be purchased for approximately $65.00.

Ingevity has a market capitalization of $2.72 billion and generates $1.29 billion in revenue each year. The company earns $183.70 million in net income (profit) each year or $4.93 on an earnings per share basis. Ingevity employs 1,750 workers across the globe.View Additional Information About Ingevity.

The official website for Ingevity is http://www.ingevity.com/.

Ingevity's mailing address is 5255 Virginia Avenue, North Charleston SC, 29406. The company can be reached via phone at 843-740-2300 or via email at [email protected]